ASH 2014 | Prof Claire Harrison at ASH 2014 Highlights on myeloproliferative neoplasms
A molecular-based approach in MPN studies, which has improved understanding of driver mutations, has rapidly increased recent advances in clinical management. Combinational therapies are in preliminary stages and focus is on the Janus kinase (JAK) inhibitor, ruxolitinib, in combinations that enhance overall patient response. Long-term studies, such as the Evaluation of Xagrid Efficacy and Long-term Safety (EXELS) study, are providing insight in high-risk patients with essential thrombocythemia (ET). Quality of life in MPN patients is also addressed.
Get great new content delivered to your inboxSign up